Ken Griffin Adaptimmune Therapeutics PLC Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Citadel Advisors LLC holds 61,900 shares of ADAP stock, worth $15,475. This represents 0.0% of its overall portfolio holdings.

Number of Shares

61,900

Previous 14,700 321.09%

Holding current value

$15,475

Previous $7,000 71.43%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$0.54 - $0.95 $94,528 - $166,299	175,052 New	175,052 $94,000
Q2 2024 Aug 14, 2024	SELL	$0.83 - $1.47 $83,664 - $148,176	-100,800 Reduced 41.36%	142,891 $140,000
Q1 2024 May 15, 2024	SELL	$0.7 - $1.75 $2.21 Million - $5.52 Million	-3,155,823 Reduced 92.83%	243,691 $385,000
Q4 2023 Feb 14, 2024	SELL	$0.43 - $0.79 $64,519 - $118,535	-150,045 Reduced 4.23%	3,399,514 $2.69 Million
Q3 2023 Nov 14, 2023	BUY	$0.73 - $1.04 $131,017 - $186,655	179,476 Added 5.33%	3,549,559 $2.77 Million
Q2 2023 Aug 14, 2023	BUY	$0.9 - $1.51 $2.02 Million - $3.39 Million	2,243,065 Added 199.03%	3,370,083 $3.1 Million
Q1 2023 May 15, 2023	BUY	$1.06 - $2.16 $937,443 - $1.91 Million	884,381 Added 364.49%	1,127,018 $1.23 Million
Q4 2022 Feb 14, 2023	SELL	$1.05 - $2.53 $1.36 Million - $3.28 Million	-1,295,049 Reduced 84.22%	242,637 $354,000
Q3 2022 Nov 14, 2022	BUY	$1.06 - $2.41 $33,422 - $75,989	31,531 Added 2.09%	1,537,686 $1.65 Million
Q2 2022 Aug 15, 2022	SELL	$1.33 - $2.28 $322,306 - $552,526	-242,336 Reduced 13.86%	1,506,155 $2.56 Million
Q1 2022 May 16, 2022	BUY	$1.73 - $4.06 $383,042 - $898,932	221,412 Added 14.5%	1,748,491 $3.6 Million
Q4 2021 Feb 14, 2022	SELL	$3.5 - $5.68 $4.07 Million - $6.61 Million	-1,164,049 Reduced 43.26%	1,527,079 $5.73 Million
Q3 2021 Nov 15, 2021	BUY	$3.44 - $6.37 $8.74 Million - $16.2 Million	2,540,526 Added 1686.91%	2,691,128 $13.9 Million
Q2 2021 Aug 16, 2021	SELL	$3.86 - $5.78 $8.97 Million - $13.4 Million	-2,324,950 Reduced 93.92%	150,602 $641,000
Q1 2021 May 17, 2021	BUY	$4.9 - $6.83 $2.67 Million - $3.72 Million	544,888 Added 28.22%	2,475,552 $13.1 Million
Q4 2020 Feb 16, 2021	SELL	$4.0 - $9.2 $11.8 Million - $27.2 Million	-2,960,382 Reduced 60.53%	1,930,664 $10.4 Million
Q3 2020 Nov 16, 2020	BUY	$7.66 - $10.78 $13 Million - $18.3 Million	1,701,878 Added 53.36%	4,891,046 $39 Million
Q2 2020 Aug 14, 2020	BUY	$2.58 - $12.1 $2.93 Million - $13.7 Million	1,135,963 Added 55.33%	3,189,168 $31.9 Million
Q1 2020 May 15, 2020	BUY	$1.2 - $4.52 $2.46 Million - $9.28 Million	2,053,205 New	2,053,205 $5.59 Million
Q4 2019 Feb 14, 2020	SELL	$0.72 - $1.43 $13,652 - $27,115	-18,962 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$1.43 - $3.81 $85,503 - $227,811	-59,793 Reduced 75.92%	18,962 $28,000
Q2 2019 Aug 14, 2019	BUY	$3.23 - $5.41 $19,667 - $32,941	6,089 Added 8.38%	78,755 $317,000
Q1 2019 May 15, 2019	BUY	$3.63 - $6.06 $166,537 - $278,020	45,878 Added 171.26%	72,666 $0
Q4 2018 Feb 14, 2019	SELL	$3.76 - $14.16 $817,803 - $3.08 Million	-217,501 Reduced 89.03%	26,788 $154,000
Q3 2018 Nov 13, 2018	BUY	$8.27 - $13.56 $1.08 Million - $1.78 Million	131,009 Added 115.65%	244,289 $0
Q2 2018 Aug 10, 2018	BUY	$10.42 - $13.74 $1.18 Million - $1.56 Million	113,280 New	113,280 $0
Q4 2017 Feb 09, 2018	SELL	$6.68 - $8.74 $557,265 - $729,117	-83,423 Closed	0 $0
Q3 2017 Nov 09, 2017	BUY	$4.93 - $8.93 $411,275 - $744,967	83,423	83,423 $683,000

Others Institutions Holding ADAP

# of Institutions

Shares Held

114M

Call Options Held

77.5K

Put Options Held

14.2K

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $40.8M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account